Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA5A | P35218 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564036 | 0.82 | CA2 (0.44) | CA2CA1CA5ACA9SMN1; SMN2 | |
| SCHEMBL8526438 | 0.82 | CA2 (0.52) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL776395 | 0.81 | GABRA1 (0.42) | GABRA1GABRB2LMNACTSBPSIP1 | |
| SCHEMBL4789537 | 0.80 | CA2 (0.50) | CA2CA1CA5ACA9CA12 | |
| Hydrochloric Acid SCHEMBL21048862 | 0.80 | CA2 (0.50) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL30297591 | 0.80 | CA2 (0.50) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL8607414 | 0.79 | GABRA1 (0.65) | CA2CA1CA5ACA9GABRA1 | |
| SCHEMBL9256894 | 0.79 | GABRA1 (0.41) | CA2CA1GABRA1GABRB2LMNA | |
| Hydrochloric Acid SCHEMBL7559869 | 0.78 | CA2 (0.48) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL449211 | 0.77 | CA2 (0.52) | CA2CA1CA5ACA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-04-04 | — | — | US | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| EP-3087091-B1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2021-10-20 | — | — | EP | disclosed |
| CN-111333588-A | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | disclosed |
| CN-104066724-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-04-17 | — | — | CN | disclosed |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| CN-110143999-A | Have cytotoxicity and antimitotic compound and its application method | 酵活有限公司 | 2019-08-20 | — | — | CN | disclosed |
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2019-02-12 | — | — | US | disclosed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | disclosed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| CN-106459162-A | VAR2CSA-drug conjugates | 酵活有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9522876-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2016-12-20 | — | — | US | disclosed |
| EP-3087091-A1 | VAR2CSA-DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | disclosed |
| CN-105358174-A | Cytotoxic and antimitotic compounds and methods of use thereof | CT FOR DRUG RES AND DEV | 2016-02-24 | — | — | CN | disclosed |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| WO-2015095952-A1 | VAR2CSA-DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | CA2 3340/4885CA1 2522/4885CA5A 2410/4885 |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CA2 3603/4885CA1 2505/4885CA5A 1588/4885 |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, CCNB2, CCNB3 | CA2 2860/4885CA1 1723/4885CA5A 1290/4885 |
| US-10675355-B2 | VAR2CSA-drug conjugates | VARS1, GUSB, VAV1 | CA2 3340/4885CA1 2522/4885CA5A 2410/4885 |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | CA2 3340/4885CA1 2522/4885CA5A 2410/4885 |
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, CCNB2 | CA2 3627/4885CA1 2583/4885CA5A 1627/4885 |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CA2 3603/4885CA1 2505/4885CA5A 1588/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CA2 3603/4885CA1 2505/4885CA5A 1588/4885 |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CA2 3603/4885CA1 2505/4885CA5A 1588/4885 |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, CCNB2 | CA2 3627/4885CA1 2583/4885CA5A 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.